CH631701A5 - Process for preparing N-substituted 2-amino-cyclopent-1-ene-1-dithiocarboxylic acids - Google Patents
Process for preparing N-substituted 2-amino-cyclopent-1-ene-1-dithiocarboxylic acids Download PDFInfo
- Publication number
- CH631701A5 CH631701A5 CH1582477A CH1582477A CH631701A5 CH 631701 A5 CH631701 A5 CH 631701A5 CH 1582477 A CH1582477 A CH 1582477A CH 1582477 A CH1582477 A CH 1582477A CH 631701 A5 CH631701 A5 CH 631701A5
- Authority
- CH
- Switzerland
- Prior art keywords
- acid
- cyclopent
- amino
- dopamine
- dithiocarboxylic
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 24
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 24
- 229960002748 norepinephrine Drugs 0.000 description 24
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 16
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 15
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 13
- 229960003638 dopamine Drugs 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000004100 adrenal gland Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229940076279 serotonin Drugs 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- GCZZOZBWAZHCAN-UHFFFAOYSA-N 1-phenyl-3-(1,3-thiazol-2-yl)thiourea Chemical compound C=1C=CC=CC=1NC(=S)NC1=NC=CS1 GCZZOZBWAZHCAN-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- NXJOFTRBTBDSHB-UHFFFAOYSA-N (4-methyl-1,4-diazepane-1-carbothioyl)sulfanyl 4-methyl-1,4-diazepane-1-carbodithioate Chemical compound C1CN(C)CCCN1C(=S)SSC(=S)N1CCN(C)CCC1 NXJOFTRBTBDSHB-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- -1 aliphatic thiocarbamide derivatives Chemical class 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 3
- 229960002563 disulfiram Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- OFELWPIUPPMBTA-UHFFFAOYSA-N Oosponol Natural products OCC(=O)C1=Cc2cccc(O)c2C(=O)O1 OFELWPIUPPMBTA-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229950004394 ditiocarb Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- WRIZJEREXIDJCC-UHFFFAOYSA-N oosponol Chemical compound C1=CC=C2C(C(=O)CO)=COC(=O)C2=C1O WRIZJEREXIDJCC-UHFFFAOYSA-N 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- QYPKEVDTCBHOMB-UHFFFAOYSA-N ClC=1N=C(C(=O)O)C=CC1CCC Chemical compound ClC=1N=C(C(=O)O)C=CC1CCC QYPKEVDTCBHOMB-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940116901 diethyldithiocarbamate Drugs 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WREDNSAXDZCLCP-UHFFFAOYSA-N methanedithioic acid Chemical compound SC=S WREDNSAXDZCLCP-UHFFFAOYSA-N 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940042794 thiocarbamide derivative for treatment of tuberculosis Drugs 0.000 description 1
- 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU76RI610A HU175526B (hu) | 1976-12-30 | 1976-12-30 | Sposob poluchenija 2-amino-ciklopent-1-en-1-ditiokarbonovykh-disul'fidov |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH631701A5 true CH631701A5 (en) | 1982-08-31 |
Family
ID=11001014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1582477A CH631701A5 (en) | 1976-12-30 | 1977-12-21 | Process for preparing N-substituted 2-amino-cyclopent-1-ene-1-dithiocarboxylic acids |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPS5384949A (enExample) |
| AR (1) | AR216308A1 (enExample) |
| AT (1) | AT351501B (enExample) |
| AU (1) | AU516353B2 (enExample) |
| BE (1) | BE862408A (enExample) |
| CH (1) | CH631701A5 (enExample) |
| DE (1) | DE2758809A1 (enExample) |
| ES (1) | ES465567A1 (enExample) |
| FI (1) | FI66595C (enExample) |
| FR (1) | FR2376132A1 (enExample) |
| GB (1) | GB1582716A (enExample) |
| HU (1) | HU175526B (enExample) |
| IL (1) | IL53646A (enExample) |
| IN (1) | IN146470B (enExample) |
| NL (1) | NL7714514A (enExample) |
| NO (1) | NO145237C (enExample) |
| PT (1) | PT67482B (enExample) |
| SE (1) | SE7714526L (enExample) |
| SU (1) | SU743580A3 (enExample) |
| YU (1) | YU309677A (enExample) |
| ZA (1) | ZA777573B (enExample) |
-
1976
- 1976-12-30 HU HU76RI610A patent/HU175526B/hu unknown
-
1977
- 1977-12-19 IL IL53646A patent/IL53646A/xx unknown
- 1977-12-20 ZA ZA00777573A patent/ZA777573B/xx unknown
- 1977-12-20 AT AT912077A patent/AT351501B/de not_active IP Right Cessation
- 1977-12-20 SE SE7714526A patent/SE7714526L/ not_active Application Discontinuation
- 1977-12-21 CH CH1582477A patent/CH631701A5/de not_active IP Right Cessation
- 1977-12-23 AU AU31979/77A patent/AU516353B2/en not_active Expired
- 1977-12-26 FR FR7739183A patent/FR2376132A1/fr active Granted
- 1977-12-27 IN IN1772/CAL/77A patent/IN146470B/en unknown
- 1977-12-27 YU YU03096/77A patent/YU309677A/xx unknown
- 1977-12-28 SU SU772559902A patent/SU743580A3/ru active
- 1977-12-28 BE BE183912A patent/BE862408A/xx not_active IP Right Cessation
- 1977-12-29 AR AR270573A patent/AR216308A1/es active
- 1977-12-29 FI FI773967A patent/FI66595C/fi not_active IP Right Cessation
- 1977-12-29 NL NL7714514A patent/NL7714514A/xx not_active Application Discontinuation
- 1977-12-29 NO NO774502A patent/NO145237C/no unknown
- 1977-12-29 JP JP15853077A patent/JPS5384949A/ja active Pending
- 1977-12-29 GB GB54173/77A patent/GB1582716A/en not_active Expired
- 1977-12-29 ES ES465567A patent/ES465567A1/es not_active Expired
- 1977-12-29 PT PT67482A patent/PT67482B/pt unknown
- 1977-12-30 DE DE19772758809 patent/DE2758809A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AT351501B (de) | 1979-07-25 |
| BE862408A (fr) | 1978-04-14 |
| FI66595B (fi) | 1984-07-31 |
| JPS5384949A (en) | 1978-07-26 |
| FI773967A7 (fi) | 1978-07-01 |
| IN146470B (enExample) | 1979-06-09 |
| SU743580A3 (ru) | 1980-06-25 |
| PT67482B (en) | 1979-05-30 |
| AU516353B2 (en) | 1981-05-28 |
| FI66595C (fi) | 1984-11-12 |
| NO774502L (no) | 1978-07-03 |
| SE7714526L (sv) | 1978-07-01 |
| DE2758809A1 (de) | 1978-07-06 |
| NL7714514A (nl) | 1978-07-04 |
| ATA912077A (de) | 1979-01-15 |
| YU309677A (en) | 1983-01-21 |
| GB1582716A (en) | 1981-01-14 |
| ZA777573B (en) | 1978-10-25 |
| AR216308A1 (es) | 1979-12-14 |
| ES465567A1 (es) | 1979-01-01 |
| NO145237C (no) | 1982-02-10 |
| IL53646A (en) | 1982-03-31 |
| HU175526B (hu) | 1980-08-28 |
| FR2376132B1 (enExample) | 1979-10-19 |
| PT67482A (en) | 1978-01-01 |
| IL53646A0 (en) | 1978-03-10 |
| FR2376132A1 (fr) | 1978-07-28 |
| NO145237B (no) | 1981-11-02 |
| AU3197977A (en) | 1979-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2143745A1 (de) | 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung | |
| CH645354A5 (de) | Chinolyl-guanidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mischungen. | |
| DE2460929C2 (enExample) | ||
| DE2446100C3 (de) | Phenoxyalkancarbonsäureamide von Thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und Arzneimittel | |
| CH631701A5 (en) | Process for preparing N-substituted 2-amino-cyclopent-1-ene-1-dithiocarboxylic acids | |
| DE2817078C2 (de) | Guanidinderivate | |
| DE2726793A1 (de) | 2-imino-3-aminothiazolidine | |
| DE2609746A1 (de) | Piperazinverbindungen sowie arzneimittel, die diese verbindungen enthalten | |
| DE2835043A1 (de) | Bromhexin-derivate mit gegenueber bromhexin geringerer schleimloesender und hustenlindernder wirkung und geringerer toxizitaet | |
| DE2328896A1 (de) | Quaternaere phenylcycloalkylammoniumverbindungen und daraus hergestellte arzneipraeparate | |
| DE2429756A1 (de) | N-alkyl-0-(2-(2-alkyl-5-nitro-l-imidazolyl)-aethyl)-thiocarbamate, ihre salze, verfahren zu ihrer herstellung und arzneimittel | |
| DE2113489C3 (de) | 2-Nitro-benzofuranderivate, ein Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel | |
| CH631966A5 (de) | Verfahren zur herstellung von 2-amino-cyclopent-1-en-1-thiocarbonyl-disulfiden. | |
| DE2901914C2 (de) | Zinksalz der 6-N-Acetylamino-capronsäure, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel | |
| DE2754148A1 (de) | Substituierte aminoaethanole, verfahren zu ihrer herstellung und ihre verwendung als arzneistoffe | |
| CH641167A5 (en) | N-Cyano-N'-(2-((4-methyl-5-imidazolyl)-methylthio)ethyl)-N''-alkyny l guanidines | |
| CH649536A5 (de) | Wasserloesliche derivate von 6,6'-methylen-bis(2,2,4-trimethyl-1,2-dihydrochinolin) und verfahren zur herstellung derselben. | |
| DE842071C (de) | Verfahren zur Herstellung von Phenoxyacetamidinen | |
| DE2145686C3 (de) | 2-Chlor-S-sulfamylbenzoesäurederivate, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten | |
| DE2049115A1 (en) | 5-butyl-and5-pentyl-picolinic acids active - as dopamene-b-hydroxylase inhibitors | |
| DE2250449C3 (de) | N-disubstituierte Aminoäthylester der Vincaminsäure und Verfahren zu ihrer Herstellung | |
| AT300810B (de) | Verfahren zur Herstellung neuer Pyridoxinderivate | |
| DE1493902C3 (de) | N-(N-AcylaminoacyOaminoacetonitrile, Verfahren zu ihrer Herstellung und diese enthaltende Mittel | |
| SU407551A1 (ru) | Стимулятор роста растений | |
| US4199598A (en) | Method of treating noradrenaline dysfunction or for dopamine-β-hydroxylase inhibition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |